CoChat

Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis

Open access

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Abstract

CD4+CD25+ regulatory T cells (T reg cells) play a key role in controlling autoimmunity and inflammation. Therefore, therapeutic agents that are capable of elevating numbers or increasing effector functions of this T cell subset are highly desirable. In a previous report we showed that a superagonistic monoclonal antibody specific for rat CD28 (JJ316) expands and activates T reg cells in vivo and upon short-term in vitro culture. Here we demonstrate that application of very low dosages of the CD28 superagonist into normal Lewis rats is sufficient to induce T reg cell expansion in vivo without the generalized lymphocytosis observed with high dosages of JJ316. Single i.v. administration of a low dose of the CD28 superagonist into Dark Agouti (DA) rats or Lewis rats that suffered from experimental autoimmune encephalomyelitis (EAE) proved to be highly and equally efficacious as high-dose treatment. Finally, we show that T reg cells that were isolated from CD28-treated animals displayed enhanced suppressive activity toward myelin basic protein–specific T cells in vitro, and, upon adoptive transfer, protected recipients from EAE. Our data indicate that this class of CD28-specific monoclonal antibodies targets CD4+CD25+ T reg cells and provides a novel means for the effective treatment of multiple sclerosis and other autoimmune diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20051060

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. In vivo dose-response titration of mAb JJ316. Adult Lewis rats were injected i.v. with the three indicated amounts of mAb JJ316. 3 d after injection, peripheral LNCs and splenocytes were analyzed for the prevalence of CD4+CD25+ and CD4+CD25− cells by FACS analysis. (A) Representative dot plots of CD4 and CD25 expression in lymph nodes and spleens of control or JJ316-treated animals; the figure indicates the percentages of cells in the respective quadrant. (B) The proportion of CD25+ among CD4+ cells is summarized for all animals analyzed. Absolute cell numbers were obtained by multiplying total cell numbers with the relative cell numbers obtained by FACS analysis (C). The plots in (B) and (C) show pooled data obtained on eight different occasions. Each circle represents one animal (i.e., 2 to 12 animals per group). Horizontal bars indicate medians. Mann-Whitney rank sum tests were performed between groups as indicated by the brackets, and the respective P values are given.
Figure 1. In vivo dose-response titration of mAb JJ316. Adult Lewis rats were injected i.v. with the three indicated amounts of mAb JJ316. 3 d after injection, peripheral LNCs and splenocytes were analyzed for the prevalence of CD4+CD25+ and CD4+CD25− cells by FACS analysis. (A) Representative dot plots of CD4 and CD25 expression in lymph nodes and spleens of control or JJ316-treated animals; the figure indicates the percentages of cells in the respective quadrant. (B) The proportion of CD25+ among CD4+ cells is summarized for all animals analyzed. Absolute cell numbers were obtained by multiplying total cell numbers with the relative cell numbers obtained by FACS analysis (C). The plots in (B) and (C) show pooled data obtained on eight different occasions. Each circle represents one animal (i.e., 2 to 12 animals per group). Horizontal bars indicate medians. Mann-Whitney rank sum tests were performed between groups as indicated by the brackets, and the respective P values are given.CC BY-NC-SA · PubMed Central
Figure 2. Direct monitoring of T reg and Tconv cell proliferation upon superagonistic anti-CD28 stimulation in vivo. T reg and Tconv cells were purified from pooled spleens and lymph nodes, labeled with CFSE, and adoptively transferred into syngeneic recipients. 0.1 mg of mAb JJ316 or control mAb MOPC-31C was injected on the following day. CFSE dilution was analyzed 2 d after antibody injection (A). Percentages represent the proportion of undivided cells among transferred cells. The result of one of at least three experiments is shown. (B) CD25 expression on transferred T reg and Tconv cells isolated from MOPC-31C–treated or JJ316-treated animals was determined by counter-staining with anti-CD25 mAb. (C) CFSE dye dilution among, and CD25 expression on, Tconv cells were assessed after stimulation with 1 mg of JJ316.
Figure 2. Direct monitoring of T reg and Tconv cell proliferation upon superagonistic anti-CD28 stimulation in vivo. T reg and Tconv cells were purified from pooled spleens and lymph nodes, labeled with CFSE, and adoptively transferred into syngeneic recipients. 0.1 mg of mAb JJ316 or control mAb MOPC-31C was injected on the following day. CFSE dilution was analyzed 2 d after antibody injection (A). Percentages represent the proportion of undivided cells among transferred cells. The result of one of at least three experiments is shown. (B) CD25 expression on transferred T reg and Tconv cells isolated from MOPC-31C–treated or JJ316-treated animals was determined by counter-staining with anti-CD25 mAb. (C) CFSE dye dilution among, and CD25 expression on, Tconv cells were assessed after stimulation with 1 mg of JJ316.CC BY-NC-SA · PubMed Central
Figure 3. Phenotypic analysis of T reg and Tconv cells from treated animals. 3 d after administration of 1 mg JJ316, lymph node and spleen cells were stained at the cell surface with mAbs against CD4 and CD25, followed by intracellular staining for FoxP3 and CTLA-4. Control animals were injected with PBS only. (A) Representative expression of CD25 and FoxP3 on gated CD4+ cells. The figure indicates the percentages of cells in the respective quadrant. (B) Detection of FoxP3 expression by Western blot analysis. CD4+CD25+ and CD4+CD25− T cells were purified from untreated or JJ316-treated animals (1 mg), and protein lysates from whole cells were generated. FoxP3 expression was detected with a polyclonal rabbit-anti–mouse FoxP3 IgG. Lysates from cells purified after JJ316 treatment also were diluted serially and protein loading was assessed with polyclonal anti–rat ERK-2 Ig. The experiment was repeated with a similar result. (C) Representative anti–CTLA-4 staining profiles of CD4+CD25+FoxP3+ cells are depicted (filled line graphs). Staining specificity was controlled by preincubation with unconjugated anti–CTLA-4 mAb (gray profile). A repeat experiment rendered similar results.
Figure 3. Phenotypic analysis of T reg and Tconv cells from treated animals. 3 d after administration of 1 mg JJ316, lymph node and spleen cells were stained at the cell surface with mAbs against CD4 and CD25, followed by intracellular staining for FoxP3 and CTLA-4. Control animals were injected with PBS only. (A) Representative expression of CD25 and FoxP3 on gated CD4+ cells. The figure indicates the percentages of cells in the respective quadrant. (B) Detection of FoxP3 expression by Western blot analysis. CD4+CD25+ and CD4+CD25− T cells were purified from untreated or JJ316-treated animals (1 mg), and protein lysates from whole cells were generated. FoxP3 expression was detected with a polyclonal rabbit-anti–mouse FoxP3 IgG. Lysates from cells purified after JJ316 treatment also were diluted serially and protein loading was assessed with polyclonal anti–rat ERK-2 Ig. The experiment was repeated with a similar result. (C) Representative anti–CTLA-4 staining profiles of CD4+CD25+FoxP3+ cells are depicted (filled line graphs). Staining specificity was controlled by preincubation with unconjugated anti–CTLA-4 mAb (gray profile). A repeat experiment rendered similar results.CC BY-NC-SA · PubMed Central
Figure 4. Functional analysis of T reg and Tconv cells from JJ316-treated animals ex vivo. (A) Purified T reg and Tconv cells from the lymph nodes of animals treated as indicated 3 d before isolation were cocultured with CFSE-labeled CD4+CD25− T cells from the PBS-treated animal (indicator T cells), and stimulated with costimulatory beads for 5 d. Line graphs show proliferations of indicator T cells in the absence (gray shadow) or the presence of T reg or Tconv cells at a 1:1 ratio (black line). (B) T reg and Tconv cell/indicator T cell ratios of 1:1, 1:5, and 1:10 were determined by translating CFSE dilution profiles into the average number of cell divisions of the indicator T cells after 5 d of culture. The symbols indicate proliferation of indicator T cells in the absence of T reg/Tconv cells (open diamonds) or in the presence of T reg/Tconv cells from the animal treated with PBS (filled circles), 0.1 mg JJ316 (open squares), or 1 mg JJ316 (gray diamonds). The result is representative of two experiments performed.
Figure 4. Functional analysis of T reg and Tconv cells from JJ316-treated animals ex vivo. (A) Purified T reg and Tconv cells from the lymph nodes of animals treated as indicated 3 d before isolation were cocultured with CFSE-labeled CD4+CD25− T cells from the PBS-treated animal (indicator T cells), and stimulated with costimulatory beads for 5 d. Line graphs show proliferations of indicator T cells in the absence (gray shadow) or the presence of T reg or Tconv cells at a 1:1 ratio (black line). (B) T reg and Tconv cell/indicator T cell ratios of 1:1, 1:5, and 1:10 were determined by translating CFSE dilution profiles into the average number of cell divisions of the indicator T cells after 5 d of culture. The symbols indicate proliferation of indicator T cells in the absence of T reg/Tconv cells (open diamonds) or in the presence of T reg/Tconv cells from the animal treated with PBS (filled circles), 0.1 mg JJ316 (open squares), or 1 mg JJ316 (gray diamonds). The result is representative of two experiments performed.CC BY-NC-SA · PubMed Central
Figure 5. Therapeutic potential of superagonistic CD28-specific mAb JJ316 on active EAE of the Lewis and the DA rat. (A) To induce EAE in DA rats, animals were immunized with 100 μg recombinant human MOG in CFA at day 0. mAb JJ316 (1 mg) was administered i.v. to groups of animals (n = 8) at day 0 (induction of EAE, open squares), day 10 (onset of EAE, open circles), or on days 0 and 10 (open triangles). Control animals (n = 5) were injected with 1 mg of MOPC-31C at the different time points as indicated. Animals were scored for clinical signs of EAE as described in Material and methods. (B) Therapeutic application of 0.3 mg, 0.1 mg, or 0.03 mg of JJ316 after onset of disease (day 10, arrow) protected DA rats (n = 6) immediately from severe EAE. Control animals were injected with 0.3 mg of MOPC-31C or 0.1 mg of the conventional anti-CD28 mAb JJ319. Mann-Whitney U-tests comparing JJ316- and sham-treated rats on days 13 and 14 after disease onset were significant (P < 0.05) for animals receiving 0.03 mg of JJ316 and highly significant (P < 0.01) for animals receiving 0.3 mg of JJ316. (C) Active EAE of the Lewis rat was induced by immunization with gpMBP in CFA in the hind footpad at day 0. On day 11 (arrow), animals received a single injection of 1 mg of an isotype control antibody (filled circles); a single injection of 0.1 mg, 0.3 mg, or 1 mg of mAb JJ316; or were administered 2 mg of methylprednisolone on five consecutive days. P values of Mann-Whitney rank sum tests of clinical scores that compared the isotype-treated group with the JJ316-treated groups on days 13, 14, and 15 were all significant; most were highly significant.
Figure 5. Therapeutic potential of superagonistic CD28-specific mAb JJ316 on active EAE of the Lewis and the DA rat. (A) To induce EAE in DA rats, animals were immunized with 100 μg recombinant human MOG in CFA at day 0. mAb JJ316 (1 mg) was administered i.v. to groups of animals (n = 8) at day 0 (induction of EAE, open squares), day 10 (onset of EAE, open circles), or on days 0 and 10 (open triangles). Control animals (n = 5) were injected with 1 mg of MOPC-31C at the different time points as indicated. Animals were scored for clinical signs of EAE as described in Material and methods. (B) Therapeutic application of 0.3 mg, 0.1 mg, or 0.03 mg of JJ316 after onset of disease (day 10, arrow) protected DA rats (n = 6) immediately from severe EAE. Control animals were injected with 0.3 mg of MOPC-31C or 0.1 mg of the conventional anti-CD28 mAb JJ319. Mann-Whitney U-tests comparing JJ316- and sham-treated rats on days 13 and 14 after disease onset were significant (P < 0.05) for animals receiving 0.03 mg of JJ316 and highly significant (P < 0.01) for animals receiving 0.3 mg of JJ316. (C) Active EAE of the Lewis rat was induced by immunization with gpMBP in CFA in the hind footpad at day 0. On day 11 (arrow), animals received a single injection of 1 mg of an isotype control antibody (filled circles); a single injection of 0.1 mg, 0.3 mg, or 1 mg of mAb JJ316; or were administered 2 mg of methylprednisolone on five consecutive days. P values of Mann-Whitney rank sum tests of clinical scores that compared the isotype-treated group with the JJ316-treated groups on days 13, 14, and 15 were all significant; most were highly significant.CC BY-NC-SA · PubMed Central
Figure 6. mAb JJ316-primed T reg cells suppress the proliferation of gpMBP-specific T cells in vitro. T reg and Tconv cells were isolated from the draining lymph nodes of animals that had been immunized with gpMBP in CFA 9 d before functional analysis. mAb JJ316 (0.1 mg or 1 mg per animal) or PBS was administered 3 d before the in vitro suppression assay. Conventional CD4+CD25− T cells from the PBS-treated animal (gray bars) served as indicator T cells, and were cocultured with T reg or Tconv cells from the animal treated with PBS, 0.1 mg JJ316, or 1 mg of JJ316. T cells were stimulated with gpMBP in the presence of irradiated splenic APCs. A repeat experiment rendered similar results.
Figure 6. mAb JJ316-primed T reg cells suppress the proliferation of gpMBP-specific T cells in vitro. T reg and Tconv cells were isolated from the draining lymph nodes of animals that had been immunized with gpMBP in CFA 9 d before functional analysis. mAb JJ316 (0.1 mg or 1 mg per animal) or PBS was administered 3 d before the in vitro suppression assay. Conventional CD4+CD25− T cells from the PBS-treated animal (gray bars) served as indicator T cells, and were cocultured with T reg or Tconv cells from the animal treated with PBS, 0.1 mg JJ316, or 1 mg of JJ316. T cells were stimulated with gpMBP in the presence of irradiated splenic APCs. A repeat experiment rendered similar results.CC BY-NC-SA · PubMed Central
Figure 7. CD4+CD25+ T reg cells mediate reduced disease severity. Donor animals were immunized with gpMBP in CFA and received 1 mg of mAb JJ316 i.v. 3 d later, draining LNCs were prepared and separated, in part, into CD4+CD25− and CD4+CD25+ cells. Recipient animals received PBS only, 4 (4.7) × 107 total draining LNCs, 4 (4.7) × 106 purified CD4+CD25+ T cells, or 3.6 (4.2) × 107 CD4+CD25− T cells; numbers in parentheses denote the amount of cells transferred in AT-EAE (see Fig. 4 B). EAE was induced in recipient animals by active immunization with gpMBP in CFA (A) or by adoptive transfer of encephalitogenic T cell line cells (B). These experiments were reproduced twice with similar results. Generation of protective CD4+CD25+ T reg cells is related to the application of superagonistic CD28-specific mAb and is antigen priming-independent (C). On the day of immunization with gpMBP in CFA, animals received 6 × 107 JJ316-primed total draining LNCs (open squares) or 6 × 106 separated CD4+CD25+ T cells (open circles). Control treatment consisted of the transfer of 5.4 × 107 CD28 superagonist-activated CD4+CD25− T cells (gray circles) or in the administration of PBS only (black circles).
Figure 7. CD4+CD25+ T reg cells mediate reduced disease severity. Donor animals were immunized with gpMBP in CFA and received 1 mg of mAb JJ316 i.v. 3 d later, draining LNCs were prepared and separated, in part, into CD4+CD25− and CD4+CD25+ cells. Recipient animals received PBS only, 4 (4.7) × 107 total draining LNCs, 4 (4.7) × 106 purified CD4+CD25+ T cells, or 3.6 (4.2) × 107 CD4+CD25− T cells; numbers in parentheses denote the amount of cells transferred in AT-EAE (see Fig. 4 B). EAE was induced in recipient animals by active immunization with gpMBP in CFA (A) or by adoptive transfer of encephalitogenic T cell line cells (B). These experiments were reproduced twice with similar results. Generation of protective CD4+CD25+ T reg cells is related to the application of superagonistic CD28-specific mAb and is antigen priming-independent (C). On the day of immunization with gpMBP in CFA, animals received 6 × 107 JJ316-primed total draining LNCs (open squares) or 6 × 106 separated CD4+CD25+ T cells (open circles). Control treatment consisted of the transfer of 5.4 × 107 CD28 superagonist-activated CD4+CD25− T cells (gray circles) or in the administration of PBS only (black circles).CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 2

  1. 2003, Nat. Immunol., 4, 337
  2. 2004, J. Clin. Invest., 114, 1372, 10.1172/jci23215 · doi:10.1172/jci23215 · Paper page

Cited by

See all 206

Metadata

Authors
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R.
Affiliations
  • University of Würzburg (DE)
  • Universitätsklinikum Würzburg (DE)
  • 3TeGenero ImmunoTherapeutics AG, D-97076 Würzburg, Germany
  • 1Institute for Virology and Immunobiology, University of Würzburg
Venue
The Journal of Experimental Medicine
Published
2005-08-01
Volume
202
Issue
3
Pages
445-455
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2150928170
Cited by
203
References
48
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 2 · 2020: 7 · 2019: 2 · 2018: 7 · 2017: 7 · 2016: 9 · 2015: 7 · 2014: 13 · 2013: 9 · 2012: 19
FWCI
7.47
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • GRO (submittedVersion)
Funders
  • Bundesministerium für Bildung und Forschung
  • Bayerische Forschungsstiftung
  • Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords
regulatory T cells, experimental autoimmune encephalomyelitis, multiple sclerosis, adoptive T cell therapy, Treg cell expansion, immunosuppression, myelin basic protein, autoimmune disease therapy, Lewis rats, Dark Agouti rats
MeSH terms
Animals, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Dose-Response Relationship, Immunologic, Encephalomyelitis, Autoimmune, Experimental, Immunosuppression Therapy, Injections, Intravenous, Lymphocyte Activation, Multiple Sclerosis, Rats, Inbred Lew, Receptors, Interleukin-2, CD4-Positive T-Lymphocytes, CD28 Antigens, Cell Proliferation, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. https://app.cochat.ai/papers/10.1084/jem.20051060
The paper
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005). Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. The Journal of Experimental Medicine. https://doi.org/10.1084/jem.20051060

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.